Company intelligence / Profile preview

Amckaus PTY LTD

Australia

Ownership: Private
Development stage: Phase 1

Overview

Completed dosing of single ascending dose (SAD) in Phase I clinical trial of Aom0315 in Australia. Unblinded data indicated that Aom0315 is well tolerated and safe in all groups, with the highest dose being 10 times higher than the effective dose found in preclinical studies.

Therapeutic areas: Cardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

QG101-23-0

Unknown

Partnerships

Novotech (Australia) Pty Ltd

Beyond the preview

Go deeper on Amckaus PTY LTD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amckaus PTY LTD.

Explore the full profile